Burkitt lymphoma, extranodal and solid organ sites is a highly aggressive form of non-Hodgkin lymphoma characterized by rapid tumor growth. It primarily affects children and young adults and can manifest in various extranodal sites, including the gastrointestinal tract, jaw, and central nervous system. Accurate coding with ICD-10 Code C83.79 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that healthcare providers can effectively manage and treat this serious condition.
ICD-10 Code C83.79 represents Burkitt lymphoma occurring in extranodal and solid organ sites. This aggressive lymphoma is associated with the MYC gene rearrangement and can lead to significant morbidity if not diagnosed and treated promptly. This code should be used in clinical documentation and billing when the lymphoma is identified in locations outside of lymph nodes, ensuring accurate representation of the patient's condition for treatment and reimbursement purposes.
Burkitt lymphoma, extranodal and solid organ sites, is a highly aggressive B-cell neoplasm that requires immediate medical intervention. It is often associated with immunocompromised states and can progress rapidly, leading to severe complications. Early diagnosis and treatment are critical to improving patient outcomes.
ICD-10 Code C83.79 is utilized in SOAP notes to document the presence of Burkitt lymphoma in extranodal and solid organ sites. This code aids in capturing the patient's symptoms, assessment findings, and treatment plans, ensuring comprehensive documentation in both acute and chronic care settings.
In SOAP notes, ICD-10 Code C83.79 connects subjective patient-reported symptoms and objective clinical findings to a formal diagnosis of Burkitt lymphoma. This code is crucial for ensuring continuity of care, supporting accurate billing, and meeting EHR documentation standards.
Burkitt lymphoma, extranodal and solid organ sites, necessitates urgent treatment due to its aggressive nature. Hospitalization is often required for intensive therapy.


HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.
Learn moreICD-10 Code C83.79 is critical in medical billing, particularly in hospital, ER, or infectious disease care settings.
| CPT Code | Description |
|---|---|
| 96413 | Chemotherapy administration, intravenous, push technique. |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis. |
| 77021 | Magnetic resonance imaging (MRI) of the abdomen. |
| 85025 | Complete blood count (CBC) with differential. |
Common Questions About Using ICD-10 Code C83.79 for Burkitt lymphoma, extranodal and solid organ sites
What are the common symptoms of Burkitt lymphoma?
Common symptoms include rapidly growing tumors, abdominal pain, swelling, fever, and night sweats. Patients may also experience weight loss and fatigue due to the aggressive nature of the disease.
How is Burkitt lymphoma diagnosed?
Diagnosis typically involves imaging studies, biopsy of the tumor, and laboratory tests to assess the presence of MYC gene rearrangements. A thorough clinical evaluation is essential for accurate diagnosis.
What is the treatment for Burkitt lymphoma?
Treatment usually involves intensive chemotherapy regimens. In some cases, radiation therapy may be indicated. Early intervention is crucial due to the aggressive nature of the disease.
Is Burkitt lymphoma contagious?
No, Burkitt lymphoma is not contagious. It is a type of cancer that arises from genetic mutations in B-cells and is not transmitted from person to person.
Clinical Notes
SOAP notes
DAP notes
AI medical notes